Novo Nordisk(US:NVO) Ge Long Hui·2025-09-29 09:14Core Viewpoint - Novo Nordisk (NVO.US) shares fell 3% in pre-market trading following a downgrade by Morgan Stanley analyst Thibault Boutherin, who changed the rating to "sell" and reduced the target price from $99 to $47. Concerns are heightened among investors regarding potential policy changes aimed at lowering U.S. drug prices to the lowest levels among developed markets, with a deadline set by Trump for September 29 [1]. Group 1 - Novo Nordisk's pre-market price was $53.940, down $1.670 or 3.00% from the previous close [1]. - The company's market capitalization stands at $246.945 billion, with a total share count of 4.441 billion [1]. - The stock has a 52-week high of $117.250 and a low of $44.548, indicating significant volatility [1]. Group 2 - The average price of Novo Nordisk shares was $55.348, with a trading volume of 17.7398 million shares [1]. - The price-to-earnings ratio (P/E) is reported at 15.67, while the price-to-book ratio (P/B) is 9.371 [1]. - The dividend yield is noted at 3.230%, with a trailing twelve months (TTM) dividend of $1.794 [1].